Alchemab Therapeutics
Agent36Agent Readiness: 36/100. Below median. Measured by StartupHub.ai. Median 41.Discovering and developing first-in-class antibody therapeutics by identifying protective antibodies from disease-resilient individuals.
About
Alchemab Therapeutics is a clinical-stage biotechnology startup founded in 2019. The company focuses on discovering and developing novel antibody therapeutics by identifying naturally occurring protective antibodies from individuals who are resilient to specific diseases. They utilize well-defined patient samples, deep B cell sequencing, and computational analysis to identify convergent protective antibody responses.
Key facts
At-a-glance profile data
- Website
- alchemab.com
- Headquarters
- London, England, United Kingdom
- Founded
- 2019
- Total funding
- $32M (Series A)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 1 Jul 2026 | Series A | $32M | British Business Bank |
Tech stack
Detected on alchemab.com, last scanned 24 Sept 2026. Run your own scan
- Frontend
- jQuery
- Analytics
- Google Analytics 4
- CMS / Builders
- WordPress
- Hosting
- Google Cloud
- Email provider
- Microsoft 365
- Video / media
- Vimeo
Frequently asked
What does Alchemab Therapeutics do?
These identified antibodies are then developed into therapeutic products for hard-to-treat diseases.
How much funding has Alchemab Therapeutics raised?
Alchemab Therapeutics has raised a total of $32M in funding. The most recent round on record is Series A.